B
Bruce E. Johnson
Researcher at Harvard University
Publications - 523
Citations - 76494
Bruce E. Johnson is an academic researcher from Harvard University. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 104, co-authored 474 publications receiving 68801 citations. Previous affiliations of Bruce E. Johnson include University of Adelaide & Virginia Tech.
Papers
More filters
Journal ArticleDOI
Effect of Epidermal Growth Factor Receptor Tyrosine Kinase Domain Mutations on the Outcome of Patients with Non–Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
Pasi A. Jänne,Bruce E. Johnson +1 more
TL;DR: It is suggested that for patients with advanced non–small cell lung cancer bearing EGFR mutations, treatment with an EGFR TKI should be incorporated as at least part of their initial therapy.
Journal Article
Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma.
TL;DR: It is demonstrated that in vitro, ZD1839 is as effective or more effective against MPM cell lines as it is against the NSCLC cell line A549 and suggest that ZD 1839 may be an effective therapeutic option for patients with MPM.
Journal ArticleDOI
Characteristics and Outcomes of Patients With Metastatic KRAS-Mutant Lung Adenocarcinomas: The Lung Cancer Mutation Consortium Experience.
Badi El Osta,Madhusmita Behera,Sungjin Kim,Lynne D. Berry,Gabriel Sica,Rathi N. Pillai,Taofeek K. Owonikoko,Mark G. Kris,Bruce E. Johnson,David J. Kwiatkowski,Lynette M. Sholl,Dara L. Aisner,Paul A. Bunn,Fadlo R. Khuri,Suresh S. Ramalingam +14 more
TL;DR: In the LCMC study, 27% of lung adenocarcinomas patients harbored a KRAS mutation and up to one‐third of them had another oncogenic driver, and patients with both KRAS and STK11 mutations had a significantly inferior clinical outcome.
Journal ArticleDOI
Bronchioloalveolar Carcinoma and Lung Adenocarcinoma: The Clinical Importance and Research Relevance of the 2004 World Health Organization Pathologic Criteria
William D. Travis,Kavita Garg,Wilbur A. Franklin,Ignacio I. Wistuba,Bradley S. Sabloff,Masayuki Noguchi,Ryutaro Kakinuma,Maureen F. Zakowski,Michelle S. Ginsberg,Robert F. Padera,Francine L. Jacobson,Bruce E. Johnson,Fred R. Hirsch,Elizabeth Brambilla,Douglas B. Flieder,Kim R. Geisinger,Frederik B. Thunnissen,Keith M. Kerr,David F. Yankelevitz,Teri J. Franks,Jeffrey R. Galvin,Douglas W. Henderson,Andrew G. Nicholson,Philip S. Hasleton,Victor L. Roggli,Ming-Sound Tsao,Federico Cappuzzo,Madeline Vazquez +27 more
TL;DR: The clinical concept of BAC needs to be reevaluated with careful attention to the new 2004 WHO criteria because of the major clinical implications and more work is needed to determine the most important prognostic pathologic features in lung adenocarcinoma.
Journal ArticleDOI
Spatially organized multicellular immune hubs in human colorectal cancer
Karin Pelka,Matan Hofree,Jonathan H. Chen,Siranush Sarkizova,Joshua D. Pirl,Vjola Jorgji,Alborz Bejnood,Danielle Dionne,William H. Ge,Katherine Xu,Sherry X. Chao,Daniel R. Zollinger,David J. Lieb,Jason Reeves,Christopher A. Fuhrman,Margaret L. Hoang,Toni Delorey,Lan T. Nguyen,Julia Waldman,Max Klapholz,Isaac Wakiro,Ofir Cohen,Julian Albers,Christopher Smillie,Michael S. Cuoco,Jingyi Wu,Mei-Ju Su,Jason Yeung,Brinda Vijaykumar,Angela M. Magnuson,Natasha Asinovski,Tabea Moll,Max N. Goder-Reiser,Anise S. Applebaum,Lauren K. Brais,Laura DelloStritto,Sarah L. Denning,Susannah T. Phillips,Emma K. Hill,Julia K. Meehan,Dennie T. Frederick,Tatyana Sharova,Abhay Kanodia,Ellen Todres,Judit Jané-Valbuena,Moshe Biton,Benjamin Izar,Conner Lambden,Thomas E. Clancy,Ronald Bleday,Nelya Melnitchouk,Jennifer Irani,Hiroko Kunitake,David H. Berger,Amitabh Srivastava,Jason L. Hornick,Shuji Ogino,Asaf Rotem,Sébastien Vigneau,Bruce E. Johnson,Ryan B. Corcoran,Arlene H. Sharpe,Vijay K. Kuchroo,Kimmie Ng,Marios Giannakis,Linda T. Nieman,Genevieve M. Boland,Andrew J. Aguirre,Ana C. Anderson,Orit Rozenblatt-Rosen,Aviv Regev,Aviv Regev,Nir Hacohen,Nir Hacohen +73 more
TL;DR: In this paper, the authors found a myeloid cell-attracting hub at the tumor-luminal interface associated with tissue damage and an MMRd-enriched immune hub within the tumor.